Drug Profile
Research programme: antibody therapeutics - Atara Biotherapeutics
Alternative Names: AMG 777; AMG 842; ATA 777; ATA 842; ATA M43Latest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Amgen
- Developer Atara Biotherapeutics
- Class Antibodies
- Mechanism of Action Activin inhibitors; Myostatin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cachexia; Muscular atrophy; Unspecified
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for preclinical development in Cachexia in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for research development in Muscle-wasting in USA
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in USA